Dementia Big
Nicotinic acetylcholine receptors (nAChRs) have been pursued for decades as potential molecular targets to treat cognitive dysfunction in Alzheimer’s disease (AD) due to their demonstrated role in processes underlying cognition such as synaptic facilitation, and theta and gamma wave activity. Historically, activity at these receptors is facilitated in AD by use of drugs that increase the levels of their endogenous agonist acetylcholine, and more recently nAChR selective ligands have undergone clinical trials.
http://ift.tt/21sz9um
These kind of articles are always
ReplyDeletehttp://awriter.org/bestessayscom attractive and I am happy to find so many good point here in the post, writing is simply great, thanks for sharing.
http://awriter.org/bestessayscom